Abstract:TYK2 mediates signaling of IL-23, IL-12, and Type I IFN-driven responses that are critical in immune-mediated diseases. Herein, we report the design, synthesis, and structure–activity relationships (SARs) of 3-(4-(2-((1H-indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile derivatives as selective TYK2 inhibitors. Among them, compound 14l exhibited acceptable TYK2 inhibition with an IC50 value of 9 nM, showed satisfactory selectivity characteristics over the other three homologous JAK kinases, and performed good functional potency in the JAK/STAT signaling pathway on lymphocyte lines and human whole blood. In liver microsomal assay studies, the clearance rate and half-life of 14l were 11.4 mL/min/g and 121.6 min, respectively. Furthermore, in a dextran sulfate sodium colitis model, 14l reduced the production of pro-inflammatory cytokines IL-6 and TNF-α and improved the inflammation symptoms of mucosal infiltration, thickening, and edema. Taken together, 14l was a selective TYK2 inhibitor and could be used to treat immune diseases deserving further investigation.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01468?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01468</a>.11e_in_2XA4_JAK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_001.pdb">PDB</a>)11e_in_4GJ3_TYK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_002.pdb">PDB</a>)14l_in_2XA4_JAK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_003.pdb">PDB</a>)14l_in_4GJ3_TYK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_004.pdb">PDB</a>)jmcmar_ccc (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_005.xls">XLS</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_006.csv">CSV</a>)Compounds 12a–12g with different hinge binders and their enzymatic potencies (Table S1); enzymatic potencies and the metabolic stability of compounds 13a–13l (Table S2); enzymatic potencies and the metabolic stability of compounds 14a–14o (Table S3); kinome-wide selectivity profiling of compound 14l @ 0.1 μM (Table S4); 1H NMR, 13C NMR, and HRMS-ESI of 14l, respectively (Figures S1–S3); purity of 14l (Figure S4); and biological assay methods (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_007.pdf">PDF</a>)This article has not yet been cited by other publications.

Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors.

Lead identification of novel and selective TYK2 inhibitors

Discovery of 3-(4-(2-((1 H -Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1 H -pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease

Discovery of 3-(4-(2-((1h-indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1h-pyrazol-1-yl)propanenitrile Derivatives As Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease

Design, Synthesis and Activity Study of Pyridine Derivatives as Highly Effective and Selective TYK2 Inhibitors.

Design, synthesis and biological evaluation of novel N-(methyl-d3) pyridazine-3-carboxamide derivatives as TYK2 inhibitors

Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease

Novel TYK2 Inhibitors with an N -(Methyl- d 3 )pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases.

Computer-Aided Identification of Potential Tyk2 Inhibitors from Drug Database

Novel TYK2 Inhibitors with an N-(Methyl-d3)pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases

Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.

Design and Synthesis of Novel Pyrrolo[2,3-D]pyrimidine Derivatives As Potent JAK3 and SYK Dual Inhibitors

Design, Synthesis and Evaluation of Pyrrolo[2,3-D]pyrimidine-phenylamide Hybrids As Potent Janus Kinase 2 Inhibitors.

Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways

Design of a potent and selective dual JAK1/TYK2 inhibitor

Identification of pyrazolopyridine derivatives as novel spleen tyrosine kinase inhibitors.

Discovery of Imidazopyrrolopyridines Derivatives As Novel and Selective Inhibitors of JAK2.

Design, Synthesis, and Pharmacological Evaluation of 4- or 6-Phenyl-pyrimidine Derivatives As Novel and Selective Janus Kinase 3 Inhibitors.

Discovery of Potent Anti-Inflammatory 4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl) Pyrimidin-2-amines for Use As Janus Kinase Inhibitors.

Pyridopyrimidinone Derivatives As Potent And Selective C-Jun N-Terminal Kinase (Jnk) Inhibitors

Enhancing specificity in the Janus kinases: a study on the thienopyridine JAK2 selective mechanism combined molecular dynamics simulation.